第三代芳香化酶抑制剂在乳腺癌术后辅助治疗中的应用进展  

Advances research in third generation aromatase inhibitors in adjuvant therapy of postmenopausal women with early breast cancer

作　　者：徐兵河[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院肿瘤研究所内科,北京100021

出　　处：《中国癌症杂志》2005年第1期72-74,共3页China Oncology

摘　　要：　近年来,第三代芳香化酶抑制剂应用于绝经后乳腺癌的辅助治疗,取得了令人鼓舞的结果,从而对他莫昔芬在乳腺癌辅助治疗中的地位提出了挑战。第三代芳香化酶抑制剂,特别是阿那曲唑有可能首先代替他莫昔芬成为绝经后妇女乳腺癌的新的标准辅助治疗药物。本文就近年来芳香化酶抑制剂的研究进展作一介绍和评述。Recent data of third generation aromatase inhib itors in adjuvant endocrine therapy of postmenopausal women with early breast ca ncer were reviewed in this article. Aromatase inhibitors, especially anastozole, may be the first to become the new standard adjuvant endocrine therapy in opera ble breast cancer patients instead of tamoxifen.

关 键 词：乳腺肿瘤 辅助治疗 芳香化酶抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]